PROJECT SYOLIGO

RNA-BASED THERAPIES FOR RARE DISEASES: R&D FOR A SUSTAINABLE AND COMPETITIVE OLIGONUCLEOTIDE MANUFACTURING.

Ref: SIPC-20241002

SYOLIGO is an R&D and First Industrial Deployment project carried out by Sylentis for the sustainable development and manufacturing of RNA-based therapies targeting rare diseases in Spain and Europe. SYOLIGO will strengthen the technological base and enable the necessary facilities to support the sustainable growth of Sylentis as a leading pharmaceutical company in the EU.

The main objectives are: to develop RNA-based therapies for the treatment of rare diseases; to actively collaborate with IPCEI partners; to set up a new sustainable oligonucleotide production plant in Spain; to reduce the sustainability metric PMI in the oligonucleotide manufacturing process; and to introduce innovative oligonucleotide production processes.

The project is part of the IPCEI Med4Cure, approved on May 28, 2024, which comprises 14 sub-projects led by 13 companies and 11 associated partners from Belgium, Spain, France, Italy, and others. It also includes an extensive network of 175 indirect partners to ensure the dissemination of its achievements. This IPCEI supports the transition to a more sustainable and resilient health value chain, aligning with key European Union objectives.

Sylentis has been the only Spanish company selected as a direct participant in the IPCEI Med4Cure programme.

Subsidised by the CDTI.

Beneficiary entity: Sylentis, S.A.

Funding: This project has been funded by the Ministry of Science, Innovation and Universities and by the CDTI within the framework of aid for direct and associated participants in the Important Project of Common European Interest in Health (Med4Cure) and the Recovery, Transformation and Resilience Plan.

Website: https://syoligo.sylentis.com/

---

PROJECT OLIGOFASTX

Ref: MIG-20211028

OLIGOFASTX is a multidisciplinary consortium made up of two companies considered to be large companies Sylentis (PharmaMar Group), Nanovex (Química del Nalón Industrial Group) and five independent SMEs (AptusBiotech, AptaTargets, Arthex, Nostrum Biodiscovery and Biotechnology Development for Industry in Pharmaceutical), which aims to pool resources and efforts to create a comprehensive platform that facilitates and contributes to the accelerated development of oligonucleotide-based therapies in Spain. The seven entities that comprise it are specialised in the different activities necessary to complete the cycle of drug development based on oligonucleotides, creating a niche industrial fabric that facilitates the emergence of new RNA-based therapies. The project is part of Mission 8 proposed by the CDTI consisting of “Promoting technological progress and training in the Spanish biopharmaceutical industry to promote R&D actions in the field of advanced therapies, vaccines and targeted therapies”. The project is supported by the Ministry of Innovation and subsidized by the CDTI.

Visit website: www.oligofastx.com

---

PROJECT SECRETED

Ref: H2020-FNR-2020-101000794

The SECRETed project will fully exploit the potential of Synthetic and Systems Biology tools and their application within aquatic biotechnology to develop new hybrid compounds for the agrochemical, pharmaceutical, cosmetic and chemical sectors. The biosynthetic pathways of extremophile and marine microorganisms will be reverse-engineered to infer the individual functions of their constituent genes, which will be combined for the production of custom-designed biosurfactants and non-natural siderophores. Los biosurfactantes son compuestos de naturaleza tensioactiva con tendencia a adsorberse en interfases, mientras que los sideróforos tienen la capacidad de quelar y transportar iones Fe³⁺. Biosurfactants are compounds of a surface-active nature with a tendency to adsorb at interfaces, while siderophores have the ability to chelate and transport Fe3+ ions. An iterative procedure following Design-Build-Test-Learn methodological steps will be used to produce new microbial strains that support the selected genetic elements and satisfy sustainable industrial processing solutions for the production of biosurfactants and siderophores.

---

PROJECT AGRAR-IA

AGRICULTURE: Artificial Intelligence applied to the agricultural production value chain 2050
Ref: TSI-100114-2021-20
Call: AI MISSIONS (2021)

The objective of AgrarIA is to investigate Artificial Intelligence as a backbone technology with which to lay the necessary technical foundations to carry out the radical transformation of the value chain of the Spanish agri-food sector. The project is made up of a consortium of 23 public-private organizations from various sectors of activity and with the common interest of applying AI to optimize the products and services they offer to the market through the different use cases that arise. The project is funded by the Ministry of Digital Transformation and the Civil Service and is co-financed with funds from the European Union through the Recovery and Resilience Mechanism (RRM), a temporary instrument that is the core element of NextGenerationEU.

The project has been funded by the Ministry for Digital Transformation and Public Administration.